IDEXX Laboratories stock holds firm after earnings beat

Published on 09/02/2026 at 11:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock trades near USD 556.69 after a quarterly EPS beat and 9.7 percent revenue growth in the latest report.

Pop-Art-Comic: Cartoon-Tierarzt mit leuchtendem Reagenzglas und frohem Hund, Halbtonpunkte — IDEXX Laboratories US45168D1046 Pop Art Comic zeigt fröhliche Tierarzt Veterinärdiagnostik Szene mit Hund, Illustration mit AI erstellt.

IDEXX Laboratories (ISIN US45168D1046) traded at USD 556.69 after the latest report showed quarterly EPS of USD 4.27 and revenue of USD 1.22 billion. The move sits against a 12-month range of USD 518.55 to USD 769.98 and a market capitalization of about USD 43.86 billion.

Earnings still drive the story

According to a MarketBeat report, the company posted USD 4.27 in quarterly EPS, above the USD 3.94 consensus estimate by USD 0.33, and revenue rose 9.7 percent year over year to USD 1.22 billion. The same report said the prior-year quarter delivered USD 3.50 in EPS and that the full-year FY 2026 EPS guidance stands at USD 14.690 to USD 14.940.

That combination matters because the market is still valuing IDEXX at about 39.15 times earnings, while the forward view from analysts in the same data set points to USD 14.81 EPS for the current year. The share price opened at USD 556.69, keeping it well below the 52-week high of USD 769.98.

Go deeper

More on IDEXX Laboratories

Key figures, earnings context and the latest market reading in one place.

Diagnostics remain central

IDEXX Laboratories develops, manufactures and distributes products for companion-animal veterinary, livestock and poultry, dairy and water testing markets. That business mix helps explain why the latest quarter, reported for the period ended in 2026, still delivered a 25.03 percent net margin and a 71.96 percent return on equity.

Price levels to watch

Trading near USD 556.69 on September 2, 2026, the stock remains above its 52-week low of USD 518.55 and below the 52-week high of USD 769.98. For investors, the gap to the top of the range and the post-earnings valuation are the two numbers that matter most.